Haleon (HLN) Income from Non-Controlling Interests (2022 - 2025)
Haleon's (HLN) quarterly Income from Non-Controlling Interests came in at $9.4 million in Q4 2025, down 85.47% on a QoQ basis from $64.5 million in Q4 2023.
Haleon (HLN) Income from Non-Controlling Interests (2022 - 2025) Analysis & Trends
Haleon (HLN) has 3 years of Income from Non-Controlling Interests data on file, last reported at $9.4 million in Q4 2025.
- Quarterly Income from Non-Controlling Interests changed N/A year-over-year to $9.4 million in Q4 2025, while the trailing twelve-month figure through Dec 2025 was $127.0 million (changed N/A YoY) and the FY2025 annual result came in at $17.3 million, down 59.01% from the prior year.
- Income from Non-Controlling Interests eased to $9.4 million in Q4 2025, from $64.5 million in the prior quarter.
- In the past five years, Income from Non-Controlling Interests ranged from a high of $64.5 million in Q4 2023 to a low of $9.4 million in Q4 2025.
- A 3-year average of $36.4 million and a median of $31.8 million in 2023 frame the typical range for Income from Non-Controlling Interests.
- The widest YoY moves for Income from Non-Controlling Interests: up 17.07% in 2023, down 17.07% in 2023.
- Tracing HLN's Income from Non-Controlling Interests over 3 years: stood at $55.1 million in 2022, then grew by 17.07% to $64.5 million in 2023, then plunged by 85.47% to $9.4 million in 2025.
- The last three Income from Non-Controlling Interests figures came in at $9.4 million (Q4 2025), $64.5 million (Q4 2023), and $21.3 million (Q2 2023), per Business Quant data.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Inc. Minority (Qtr) |
|---|---|---|---|---|---|
| 1 | Haleon | 43.76 Bn | 42.80 Bn | - | - |
| 2 | Teva Pharmaceutical Industries | 43.05 Bn | 39.39 Bn | 2.15 Bn | - |
| 3 | Zoetis | 31.51 Bn | 29.84 Bn | 1.05 Bn | - |
| 4 | Takeda Pharmaceutical | 28.70 Bn | 22.90 Bn | 5.10 Bn | 376,434.15 |
| 5 | United Therapeutics | 22.27 Bn | 19.61 Bn | 683.80 Mn | - |
| 6 | Viatris | 18.83 Bn | 17.95 Bn | 1.46 Bn | - |
| 7 | Neurocrine Biosciences | 15.65 Bn | 15.26 Bn | 935.80 Mn | - |
| 8 | Elanco Animal Health | 12.06 Bn | 11.53 Bn | 798.00 Mn | - |
| 9 | Dr Reddys Laboratories | 10.12 Bn | 9.95 Bn | - | - |
| 10 | Alkermes | 8.27 Bn | 7.61 Bn | 397.90 Mn | - |
Historic Data
Download Data| Date | Value |
|---|---|
| Dec 31, 2025 | 9.38 Mn |
| Dec 31, 2023 | 64.54 Mn |
| Jun 30, 2023 | 21.27 Mn |
| May 3, 2023 | 31.79 Mn |
| Dec 31, 2022 | 55.13 Mn |